BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (GUARD)
Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study)
Sponsor: RedHill Biopharma Limited
This PHASE3 trial investigates Gastritis and Gastroenteritis and is currently completed. RedHill Biopharma Limited leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Feb 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RedHill Biopharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .